

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

1600 ✓

Image

Denise Ortega  
Name

Signature Derion Ortega

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bruce M. Bowman Group: 1600

Serial No.: 09/480,389 Group Art Unit: 1642

Filed : January 11, 2000 Examiner: A. Holleran

For : Immunoassays to Detect Diseases or Disease  
Susceptibility Traits

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR SECTIONS 1.56, 1.97 AND 1.98

MAIL STOP PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Washington, D.C. 20231

Sir:

The accompanying PTO Form 1449 is submitted pursuant to 37 CFR Sections 1.56, 1.97 and 1.98, directing Applicants to submit literature and information that may be considered material to the examination of the claims of an application.

Applicants respectfully submit that the instant Supplementary Information Disclosure Statement (IDS) is being submitted before a final office action under 37 CFR § 1.113. Therefore, the instant Supplementary IDS, in accordance with 37 CFR § 1.97(c).

shall be considered by the Office if filed by the applicant after the period specified in paragraph (b) of this section, provided that the information disclosure statement is filed before the mailing date of either a final action under §1.113, or a notice of allowance under §1.311, whichever occurs first and is accompanied by either:

. . .

(2) The fee set forth in §1.17(p).

Accompanying this statement is a request for payment by credit card of the fee as set forth in § 1.17(p). Should any additional fees be determined to be necessary in connection with this paper, Applicants respectfully request that any such additional fees be charged to Deposit Account No. 12-0615.


Applicants respectfully submit that the "filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in Section 1.56(b)" [37 CFR Section 1.97(h)]; and that an information disclosure statement filed in accordance with 37 CFR Section 1.97 "shall not be construed as a representation that a search has been made." [37 CFR Section 1.97(g)]

Further the identification of any document herein is not intended to be, and, Applicants respectfully submit, should not be construed as being, an admission that such a document, in fact, constitutes "prior art" within the meaning of the applicable laws, since, for example, a given document may have a later effective date than at first seems apparent, or the

document may have an effective date which can be antedated. Applicants respectfully conclude on this point that the "prior art" status of any document is a matter to be resolved during prosecution.

Thus, Applicants respectfully conclude that the citation of references herein is not intended to be an admission that any of the references are considered to be material or to constitute prior art, or that any of the references either alone or in combination with any other references would be sufficient to render any of the claims of the above-identified patent application unpatentable.

Respectfully submitted,




Leona L. Lauder  
Attorney for Applicants  
Registration No. 30,863

Dated: March 3, 2004

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CATX-N

Application Number

09/480,389

Applicant(s)

Bruce M. Bowman

Filing Date

January 11, 2000

Group Art Unit

1642

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Indicate Author, Title, Date, Pertinent Pages, Etc.)

Boddrich et al., "Reduced Neurofibromin Content but Normal Gap Activity in a Patient with Neurofibromatosis Type 1 Caused by a Five Base Pair Duplication in Exon 12B of the NF1 Gene," Biochemical and Biophysical Research Communications, 214(3): 895-904 (Sept. 25, 1995)

Czech et al., "Proteolytical processing of mutated human amyloid precursor protein in transgenic mice," Molecular Brain Research, 47: 108-116 (1997)

Mortola and Nasto, "Brown adipose tissue and its uncoupling protein in chronically hypoxic rats," Clinical Science, 93: 349-354 (1997)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.